Floatz logo

Cea-Targeted Car-T

Cholangiocarcinoma

Chongqing Precision Biotech Co., LtdCell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

92 Active assets in the Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3B
ETOMIDATE
Cheju Halla General Hospital
Phase 4B
Docetaxel
Merck Sharp & Dohme LLC
Phase 2B

View all 50 →

Same molecule, other indications

Cea-Targeted Car-T is also rated in:

rectal carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
lung cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →